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Abstract
Ischemic stroke is the leading cause of morbidity and mortality in developed countries. In 40% of cases etiology of stro-
ke is unclear. Patent foramen ovale (PFO) is present in more than half, while atrial septum aneurysm (ASA) appears in 
25% of patients with cryptogenic stroke. However, available data on the correlation between a cryptogenic stroke and 
the coexistence of PFO and ASA are limited. A lack of knowledge and recommendations in this field makes clinicians 
unsure in terms of their approach to a patient with a stroke and PFO with concomitant ASA.
The authors describe the case of a 72-year-old patient with ischemic stroke and PFO with concomitant ASA. The diag-
nostic process and treatment methods are presented. The approach is discussed in detail.
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Introduction
Ischemic stroke is one of the most common causes of 
morbidity and mortality in developed countries [1]. In 40% 
of cases the etiology of the stroke is unclear (cryptogenic 
stroke) [2]. Patent foramen ovale (PFO) is present in more 
than half, while atrial septum aneurysm (ASA) appears in 
25% of patients with cryptogenic ischemic stroke [3].
PFO is a remnant of the fetal circulation. Within the first 
year of life after birth PFO closes. However, in about 25% 
of adults foramen ovale persists. The prevalence of PFO 
in the general population decreases with age, from 34% 
in the first three decades to 20% in the ninth decade. In 
most of these patients, PFO never causes symptoms and 
is considered as a normal variant as it is found only inci-
dentally during echocardiographic investigation performed 
for other reasons [4].
ASA is a fixed displacement or a mobile excursion of 
the fossa ovalis region of the atrial septum with a total 
amplitude exceeding 10mm from the mid-line [5]. ASA has 
been identified by transesophageal echocardiography in up 
to 10% of patients.
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The postulated pathogenetic mechanism of stroke in 
patients with PFO/ASA is due to paradoxical embolus from 
the venous side. However, deep venous thrombosis is found 
only in 5–10% of stroke patients with concomitant PFO. 
Another hypothesis is that the thrombus forms in situ either 
in PFO or on the surface of the aneurysm. It also may be 
related to the atrial vulnerability to arrhythmia with regard 
to PFO and ASA presence [6]. Finally, the coexistence of PFO 
and ASA change the geometry, shape and hemodynamics 
of the atria, and affects the coordinated cooperation of 
atria, left atrial appendage and the other chambers of the 
heart. This is why coexistence of PFO and ASA is believed 
to promote similar conditions as in atrial fibrillation (AF) 
with left atrial dysfunction, which promotes thrombus 
formation [7]. Available data on the correlation between 
cryptogenic ischemic stroke and PFO with concomitant ASA 
are limited [3, 8, 9].
A lack of knowledge and recommendations on how to 
manage patients with ischemic stroke accompanied by 
coexisting PFO and ASA leads to a diagnostic and thera-
peutic dilemma.
The present paper describes the case of a 72-year-old 
patient with ischemic stroke and PFO with concomitant ASA.
Case report
A 72-year-old woman was admitted to the stroke unit at 
Nicolaus Copernicus Memorial Hospital in Lodz in the 
acute phase of ischemic stroke. Neurological examination 
revealed speech disorders and paresis of the left arm. Us-
ing the National Institutes of Health Stroke Scale (NIHSS) 
the patient gained 3 points, which means slight clinical 
symptoms of stroke. Incident of stroke was preceded by 
a transient ischemic attack presenting with weakness of 
the right upper and lower limbs.
She was a non-smoker, without a family history of neu-
rological and cardiovascular diseases.
Her medical history was notable only for rheumatoid 
arthritis, depression and glaucoma.
She was taking wenlafaxin 75mg once a day and meth-
ylprednisolone 2 mg once a day.
Her body temperature was 36.5°C, cardiac activity 
was regular (80/min) and atrial blood pressure was 
140/80 mm Hg; lung auscultation revealed a symmetrical 
normal vesicular sound, but with weakness over the base 
of the right lung. Neurological examination revealed left 
paresis of the upper limb 4+/5, discreet central paresis 
of nerve VII on the left.
All laboratory tests were normal except for elevated 
levels of platelets and C-reactive protein (Table 1). Resting 
electrocardiography (ECG) reported no irregularities. The 
chest X-ray revealed a linear atelectasis in the right lung 
base.
Transthoracic echocardiography (TTE) showed: dila-
ted cavities of both atria, neither wall thickness nor left 
ventricle wall motion abnormalities, proper left and right 
ventricular function with ejection fraction of left ventricle 
— ejection fraction (EF) 60%, a mild mitral and tricuspid 
regurgitation, possibility of pulmonary hypertension, ASA 
without leakage. Transesophageal echocardiography (TEE) 
displayed the presence of ASA with left-to-right shunt on the 
PFO at rest (diameter of shunt from 2 mm to 5 mm); occa-
sional spontaneous reversal of the shunt direction and the 
right-to-left shunt was increased by the Valsalva maneuver; 
slightly marked left ventricular spontaneous echo contrast 
(SEC); no thrombus was seen in the left atrium or in the left 
atrial appendage; the function of the left atrial appendage 
was normal on Doppler evaluation (Fig. 1).
Holter ECG did not report significant arrhythmia and 
conduction abnormalities.
A cranial computed tomography without contrast 
demonstrated multiple, diffuse vascular lesions. Carotid 
and vertebral arteries were free of atherosclerotic lesions 
without thickness of intima–media complex on Doppler 
scans and cerebral arteriography displayed no occlusion 
of cerebral arteries.
Table 1. Laboratory parameters
Parameter Value Range
Hemoglobin [g/dl] 12.5 11.4–15.5
Erythrocytes [T/l] 4.08 3.5–5.2
Hematocrit [%] 37.6 34.0–46.0
Leukocytes [G/l] 10.28 4.4–11.3
Platelets [G/l] 550 150–400
Troponin T [ng/ml] 0.03 < 0.1
Total cholesterol [mg/dl] 190 140–200
LDL-cholesterol [mg/dl] 142 < 115
HDL-cholesterol [mg/dl] 30 > 65
Triglycerides [mg/dl] 90 < 200
Creatinine [mg/dl] 0.99 0.5–0.9
Glucose [mg/dl] 87 60–99
Urea [mg/dl] 42 10–50
CRP [mg/l] 60→26 0.0–5.0
PCT [ng/ml] 0.05 0.00–0.50
AST [U/l] 25 < 31
ALT [U/l] 39 < 31
Potassium [mEq/l] 4.2 3.5–5.1
Sodium [mEq/l] 138 136–145
TSH [uIU/ml] 3.88 0.270–4.2
LDL — low-density lipoprotein; HDL — high-density lipoprotein; CRP — C-reactive protein; PCT — 
procalcitonin; AST — aspartate transaminase; ALT — alanine transaminase; TSH — thyrotropic 
hormone
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Doppler study of the lower extremities was negative 
for thrombosis.
The patient did not have any complications while 
she was hospitalized. The patient was discharged after 
9 days with final diagnoses: ischemic stroke, hypercho-
lesterolemia, PFO, ASA, rheumatoid arthritis, depression, 
glaucoma.
The patient received anticoagulant therapy with 
acenocumarol and she was referred for further assessment 
for percutaneous PFO closure.
Discussion
Available data on the correlation between the coexistence 
of PFO with cryptogenic stroke are limited. Some clinical 
and anatomical risk factors have been proposed to increase 
the likelihood of this correlation, such as: the presence of 
ASA, an amplitude of PFO > 4 mm, Chiari network, recurrent 
cryptogenic stroke, deep venous thrombosis or hereditary 
prothrombotic alterations, prolonged immobilization or 
extensive travel preceding the event.
In this regard, in patients with isolated PFO, the overall 
risk of recurrent stroke is low.
But when PFO coexists with other prothrombotic factors 
the risk of embolization can be substantial.
According to current guidelines for patients with an 
ischemic stroke or transient ischemic attack (TIA) and 
coexisting PFO, only antiplatelet therapy is recommended 
for secondary stroke prevention.
In the absence of available data, it is hard to establish 
a preferred therapy in patients with cerebrovascular event 
and the coexistence of PFO and ASA.
European Stroke Organization Guidelines for Manage-
ment of Ischemic Stroke recommends in this case antico-
agulation therapy and percutaneous PFO closure [10]. In 
contrast, guidelines of the American Heart Association/ 
/American Stroke Association for the prevention of stroke 
in patients after stroke or TIA recommend antiplatelet 
therapy. Anticoagulation with interventional treatment is 
recommended only for patients with PFO and concomitant 
deep venous thrombosis [11].
Meta-analysis of 21 clinical trials has demonstrated 
superiority of anticoagulant therapy over antiplatelet 
therapy for secondary cerebrovascular events prevention 
in the case of PFO coexistence (event rates 7.7% vs. 9.8%, 
respectively, p = 0.003). Nevertheless, anticoagulant ther-
apy was associated with over six-fold higher risk of major 
bleeding events (7.15 vs. 1.3%, respectively, p = 0.03). The 
efficacy and safety of PFO closure were also evaluated. 
PFO closure was associated with 50% relative reduction 
of recurrent cerebral events versus antiplatelet therapy 
without difference in the occurrence of major bleeding. 
Compared with anticoagulant therapy, PFO closure showed 
the same risk reduction of recurrent neurological events, 
whereas the incidence of major bleeding was reduced by 
almost 82% (15 vs 7.1%, respectively, p < 0.00001) [12].
Unfortunately, the results were obtained almost exclu-
sively from observational trials. Only one randomized-con-
trolled trial comparing the efficacy of anticoagulant and 
antiplatelet therapy (warfarin vs acetylsalicylic acid dose 
325 mg) is available. The result of this study demonstrated 
that there was no significant difference in recurrence of cer-
ebrovascular events regardless of PFO size, the presence 
of ASA or pharmacological strategy. Nevertheless, among 
the cryptogenic population there was a trend toward event 
reduction (in patients with and without PFO), but the statis-
tical power was not adequate enough to reveal superiority 
of warfarin over aspirin. The limitation of this study is that 
it included mostly elderly patients (age of study group 59 ± 
12.2 years). The mean international normalized ratio (INR) 
in the warfarin group was 2.04, which suggests that more 
aggressive anticoagulant therapy might have given different 
results. The primary end point in this study was death that 
was caused not only by recurrent ischemic stroke but also 
from any other cause [13].
Three interventional trials on endovascular PFO closure 
versus medical management have been published — 
CLOSURE I, RESPECT and PC TRIAL [14–16]. Unfortunately, 
none of these studies demonstrated a significant benefit 
for interventional treatment. Subgroups analysis of the 
RESPECT trial showed a significant efficacy of device clo-
sure among patients with ASA. This was not supported by 
other trials.
In described case, anticoagulant therapy with aceno-
cumarol was recommended until PFO closure. The main 
reason for the therapeutic decision was the coexistence of 
PFO and ASA with high risk of embolic stroke (symptoms 
involved bilateral middle cerebral artery territories on the 
same day). The other conditions that encouraged our de-
cision to apply anticoagulant treatment were: cryptogenic 
stroke, large size of PFO with occasional spontaneous 
Figure 1. Atrial septum aneurysm with left-to-right shunt in transe-
sophageal echocardiography
194
Folia Cardiologica 2017, vol. 12, no. 2
www.journals.viamedica.pl/folia_cardiologica
right-to-left shunt, the slightly marked LV spontaneous 
echo contrast (SEC), presence of predisposing factors 
for venous thromboembolism such as age > 40 years, 
ischemic stroke with paresis, autoimmune disease with 
chronic steroid therapy. No deep venous thrombosis and 
chronic steroid therapy were inconsistent with the strategy 
selected by us.
Considering the risk of thromboembolic events and 
the expected benefit/risk ratio of advantages and com-
plications, the heart/brain team in our hospital decided 
to implement anticoagulant treatment until endovascular 
PFO closure.
Conclusion
Treatment decisions for patients with stroke and PFO with 
concomitant ASA should be individualized with evaluation 
of stroke risk recurrence and bleeding complications.
In the absence of clear data it may be reasonable to 
consider anticoagulant therapy in patients with cryptogenic 
stroke and PFO with ASA. Those patients represent a group 
with high embolic stroke risk of undetermined source.
However, there is no consensus on the preferred the-
rapeutic options in patients with stroke and both PFO and 
ASA. The available evidence is based almost exclusively on 
observational trials. More randomized trials are needed 
to better define and treat these patients. In the meantime 
an optimal medical therapy for patients with cryptogenic 
stroke and both PFO and ASA is unknown and no medical 
therapy can be considered as a “gold standard”. A local 
heart/brain team should take all the decisions regarding 
the treatment of these patients.
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Streszczenie
Udar mózgu jest jedną z głównych przyczyn chorobowości i umieralności na świecie. W blisko 40% przypadków etiolo-
gia udarów niedokrwiennych mózgu pozostaje nieznana. Badania wskazują, że 50% udarów kryptogennych wiąże się 
z obecnością drożnego otworu owalnego (PFO), a 25% z obecnością tętniaka przegrody międzyprzedsionkowej (ASA). 
Jednak wyniki badań dotyczących korelacji obecności PFO i ASA z kryptogennym udarem mózgu są sprzeczne, a postę-
powanie terapeutyczne w udarze mózgu ze współistniejącymi PFO i ASA pozostaje nieustalone.
W pracy opisano przypadek 72-letniej pacjentki hospitalizowanej z powodu udaru niedokrwiennego mózgu z towarzy-
szącym świeżo rozpoznanym ASA i z PFO.
Słowa kluczowe: udar niedokrwienny mózgu, udar kryptogenny, drożny otwór owalny, tętniak przegrody międzyprzed-
sionkowej, leczenie doustnym antykoagulantem, zamknięcie PFO
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